Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases (Q34588395)

3 August 2017

1 reference

title

Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases (English)

1 reference

3 August 2017

3

Dominique Heymann

1 reference

3 August 2017

Kanji Mori

1

1 reference

3 August 2017

Kosei Ando

series ordinal

2

1 reference

3 August 2017

publication date

1 February 2008

1 reference

Expert Review of Anticancer Therapy

3 August 2017

published in

1 reference

3 August 2017

volume

8

1 reference

3 August 2017

issue

2

1 reference

3 August 2017

page(s)

151-159

1 reference

Overview of sarcomas in the adolescent and young adult population

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.151

Bone tumours in European children and adolescents, 1978-1997. Report from the Automated Childhood Cancer Information System project.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.151

Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.151

Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.151

Osteosarcoma relapse: expect the worst, but hope for the best

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.151

Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.151

21 January 2018

Macrophages and cancer

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.151

Therapy of cancer metastasis by systemic activation of macrophages: from the bench to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.151

Modulation of monocyte functions by muramyl tripeptide phosphatidylethanolamine in a phase II study in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.151

Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.151

Carrier-based strategies for targeting protein and peptide drugs to the lungs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.151

Liposomal, nanoparticle, and conjugated formulations of anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.151

Comparative pharmacokinetics of free muramyl tripeptide phosphatidyl ethanolamine (MTP-PE) and liposomal MTP-PE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.151

Prostaglandin E2 affects differently the release of inflammatory mediators from resident macrophages by LPS and muramyl tripeptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.151

Influence of chemotherapy administration on monocyte activation by liposomal muramyl tripeptide phosphatidylethanolamine in children with osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.151

Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.151

Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: a progress review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.151

Therapy of human ovarian cancer xenografts with intraperitoneal liposome encapsulated muramyl-tripeptide phosphoethanolamine (MTP-PE) and recombinant GM-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.151

Pharmacokinetics and immunomodulatory effects on monocytes during prolonged therapy with liposomal muramyltripeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.151

Liposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.151

Effect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): can ibuprofen reduce fever and chills without compromising immune stimulation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.151

Liposomal muramyl tripeptide (CGP 19835A lipid) therapy for resectable melanoma in patients who were at high risk for relapse: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.151

Prospectively planned analysis of data from a phase III study of liposomal muramyltripeptide phosphatidylethanolamine in the treatment of osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.151

Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.151

Treatment of osteosarcoma at first recurrence after contemporary therapy: the Memorial Sloan-Kettering Cancer Center experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.151

Increased Fas expression reduces the metastatic potential of human osteosarcoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.151

Interleukin-12 enhances the sensitivity of human osteosarcoma cells to 4-hydroperoxycyclophosphamide by a mechanism involving the Fas/Fas-ligand pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.151

Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.151

Interleukin-12 up-regulates Fas expression in human osteosarcoma and Ewing's sarcoma cells by enhancing its promoter activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.151

Intranasal interleukin-12 gene therapy enhanced the activity of ifosfamide against osteosarcoma lung metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.151

Eradication of osteosarcoma lung metastases following intranasal interleukin-12 gene therapy using a nonviral polyethylenimine vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.151

21 January 2018

Identifiers

DOI

10.1586/14737140.8.2.151

1 reference

3 August 2017

1 reference